Quick Answer
C4 Therapeutics, Inc. reported Stockholders Equity of $256.59 million for the year ending 2025.
- C4 Therapeutics, Inc. showed an increase of +18.8% in Stockholders Equity from 2024 to 2025.
- This data is from C4 Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2019: -$93.41 million | Q3 2019: -$102.67 million | Q1 2020: -$124.53 million | Q2 2020: -$135.06 million | Q3 2020: -$155.92 million | Q1 2021: $263.71 million | Q2 2021: $416.43 million | Q3 2021: $398.78 million | Q1 2022: $364.53 million | Q2 2022: $344.59 million | Q3 2022: $318.18 million | Q1 2023: $262.47 million | Q2 2023: $233.71 million | Q3 2023: $216.02 million | Q1 2024: $258.28 million | Q2 2024: $247.06 million | Q3 2024: $242.66 million | Q1 2025: $195.14 million | Q2 2025: $174.06 million | Q3 2025: $154.41 million.
- Over the full 8 years of available data (2018 to 2025), C4 Therapeutics, Inc.'s Stockholders Equity has grown by 421.7%.
- Historical annual values: Fiscal year 2025: $256.59 million | Fiscal year 2024: $215.99 million | Fiscal year 2023: $246.11 million | Fiscal year 2022: $289.23 million | Fiscal year 2021: $389.61 million | Fiscal year 2020: $280.79 million | Fiscal year 2019: -$111.96 million | Fiscal year 2018: -$79.75 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: